Compare ASTL & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTL | IVVD |
|---|---|---|
| Founded | 1902 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 437.1M |
| IPO Year | N/A | 2021 |
| Metric | ASTL | IVVD |
|---|---|---|
| Price | $4.14 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 1.4M | ★ 2.6M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | N/A | $147.67 |
| Revenue Next Year | $25.68 | $22.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $3.02 | $0.46 |
| 52 Week High | $7.25 | $3.07 |
| Indicator | ASTL | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 37.30 |
| Support Level | $3.99 | $0.69 |
| Resistance Level | $4.29 | $1.41 |
| Average True Range (ATR) | 0.24 | 0.13 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 82.45 | 16.28 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.